Astellas has secured an exclusive option to obtain a worldwide license for DAX-044, a novel immune-targeted IL-12 antibody-cytokine fusion being developed for immuno-oncology. The arrangement is tied to Audax’s ongoing development work for the candidate.

Under the agreement, Astellas receives the exclusive option for global development and commercialization rights. Audax retains the ability to co-fund and co-promote DAX-044 in Australia and New Zealand, while it continues funding and advancing the programme into Phase 1. The reporting frames the move as a development and partnering step that could expand DAX-044’s commercial pathway if Astellas proceeds with the license option.

The outlets largely align on the core terms—Astellas’ exclusive option for worldwide licensing and Audax’s role in continued development and early-phase progression—though they differ in emphasis: one highlights the option acquisition, while the other details the regional co-development and co-promotion structure.